Diastolic dysfunction

Current Treatment Options in Cardiovascular Medicine

Volumn 6, Issue 1, 2004, Pages 61-68

  Murphy, Sean W ^a  

^a Health Sciences Centre St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARBAMAZEPINE; CARVEDILOL; CORTICOSTEROID DERIVATIVE; CYCLOSPORIN; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXAZOSIN; FUROSEMIDE; HYDROCHLOROTHIAZIDE; ISOSORBIDE DINITRATE; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; NITRIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; QUINIDINE; SILDENAFIL; UNINDEXED DRUG; VERAPAMIL;

ACUTE KIDNEY FAILURE; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE ACTIVITY; ANXIETY DISORDER; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR DISSOCIATION; BRADYCARDIA; CLAUDICATION; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; CREATININE BLOOD LEVEL; DEPRESSION; DIARRHEA; DIASTOLE; DIZZINESS; DRUG COST; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG POTENTIATION; DYSURIA; EDEMA; EXFOLIATIVE DERMATITIS; FATIGUE; FIBROSIS; FLUSHING; HEADACHE; HEARING LOSS; HEART AFTERLOAD; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE ISCHEMIA; HEART PALPITATION; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FUNCTION; HEART VENTRICLE TACHYCARDIA; HEART VOLUME; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPERTROPHY; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; IMPOTENCE; KIDNEY DYSFUNCTION; LONGITUDINAL STUDY; METABOLIC ALKALOSIS; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NORTH AMERICA; PATIENT CARE; PHYSICIAN; PRURITUS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SHOCK; SICK SINUS SYNDROME; SIDE EFFECT; STROKE; SUPRAVENTRICULAR TACHYCARDIA; SYMPTOMATOLOGY; SYNCOPE; SYSTOLE; TACHYCARDIA; TREATMENT OUTCOME; VISUAL DISORDER; VIVID DREAM; VOMITING; XEROSTOMIA;

EID: 3142754997     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-004-0015-6     Document Type: Review

References (26)

1. Nishimura RA, Tajik AJ: Evaluation of diastolic filling of left ventricle in health and disease: Doppler echocardiography in the clinician's Rosetta Stone. J Am Coll Cardiol 1997, 30:8-18.
2. Redfield MM, Jacobsen SJ, Burnett JC, et al: Burden of systolic and diastolic venticular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003, 289:194-202.
3. American College of Cardiology: ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult. http://www.acc.org/clinical/guidelines/failure/hf_index.htm. Accessed September 1,2003.
4. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. Part I: diagnosis, prognosis, measurements of diastolic dysfunction. Circulation 2002, 105:1387-1393.
5. Zile MR, Heart failure with preserved ejection fraction: is this diastolic heart failure? J Am Coll Cardiol 2003, 41:1519-1522.
6. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure. Part II: causal mechanisms and treatment. Circulation 2002, 105:1503-1508.
7. Murphy SW: Management of heart failure and coronary artery disease in patients with chronic kidney disease. Semin Dial 2003, 16:165-172.
8. The Cardiac Insufficiency Bisoprolol Study II (CIBIS II): a randomized trial of beta-blockade in heart failure. CIBIS Investigators and Committees [no authors listed]. Lancet 1999, 353:9-13.
9. Effect of metoprolol CR/XL in chronic heart failure. Metoprolol CR/XL randomized intervention trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group [no authors listed]. Lancet 1999, 353:2001-2007.
10. Kitzman DW: Diastolic heart failure in the elderly. Heart Fail Rev 2002, 7:17-27.
11. Packer M, O'Connor CM, Ghali JK, et a.: Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996, 335:1107-1114.
12. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group [no authors listed]. N Engl J Med 1997, 336:525-533.
13. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left ventricular ejection fraction: the CHARM-preserved trial, Lancet 2003, 362:777-781.
14. Angeja BG, Grossman W: Evaluation and management of diastolic heart failure. Circulation 2003, 107:659-663.
15. Carson P, Johnson G, Fletcher R, et al.:Mild systolic dysfunction in heart failure (left ventricular ejection fraction > 35%): baseline characteristics, prognosis, failure trials (V-HeFT). J Am Coll Cardiol 1996. 27:642-649.
16. Eriksson SV, Kjekshus J, Offstad J, et al. Patient characteristics in cases of chronic severe heart failure with different degrees of left ventricular systolic dysfunction. Cardiology 1994, 85:137-144.
17. Aronow WS, Kronzon I: Effect of enalapril on congestive heart failure treated with diuretics in elderly patients with prior myocardial infarction and normal left ventricular ejection fraction. Am J Cardiol 1993, 71:602-604.
18. Philbin EF, Erb T, Jenkins P: The natural history of heart failure with preserved left ventricular systolic function. J Am Coll Cardiol 1997, 2(suppl A):245.
19. Effects of an angiotensin coverting enzyme inhibitor, remapril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Study Investigators [no authors listed]. N Engl J Med 2000, 342:145-153.
20. Lasagna L: Diuretics vs adrenergic blockers for treatment of hypertension. JAMA 2000, 283:2013-2014.
21. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Circulation 2003, 108:684-690.
22. Dahlöf B, Devereux RB, Kjeldsen SE, et al.: Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359:995-1003.
23. Warner JG, Metzeger C, Kitzman DW, et al.: Losartan improves exercise tolerance in patients with diastolic dysfunction and a hypertensive response to exercise J Am Coll Cardiol 1999, 33:1567-1572.
24. McMurray JJ, Ostergen J, Swedberg K, et al.: Effect of candersartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin coverting enzyme inhibitors: the CHARM-added trial. Lancet 2003, 362:767-771.
25. Zannad F, Dousset B, Alla F: Treatment of congestive heart failure: interfering with the aldosterone-cardiac extracellular matrix relationship. Hypertension 2001, 38:1227-1232.
26. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES] [no authors listed]. AmJ Cardiol 1996, 78:902-907.